Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s stock price hit a new 52-week low on Monday . The company traded as low as $190.15 and last traded at $190.15, with a volume of 717 shares trading hands. The stock had previously closed at $197.44.
Genmab A/S Stock Performance
The company’s 50 day moving average price is $210.08 and its 200 day moving average price is $234.92. The company has a market cap of $12.56 billion, a price-to-earnings ratio of 18.28 and a beta of 1.04.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- Pros And Cons Of Monthly Dividend Stocks
- How to Invest in Small Cap Stocks
- Why Are These Companies Considered Blue Chips?
- These Are the Dividend Stocks Insiders Bought in January
- Bank Stocks – Best Bank Stocks to Invest In
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
